

31 October 2024

IXICO PLC

("IXICO" or the "Company")

Share Option Awards

PDMR Dealing

IXICO plc (AIM: IXI), the medical imaging advanced analytics company delivering insights in neurosciences, today announces that, further to the announcements made on 8 October 2024 in respect of the Company's proposal to issue share options, and on 25 October 2024 in respect of the approval at the General Meeting of the Company's new EMI Share Option Plan, the Company has issued a total of 3,520,058 share options (the "Share Options") as follows:

Growth options:

Share Options over 2,780,058 shares have been awarded to the Bram Goorden, CEO and Grant Nash, CFO of the Company. These Growth Share Options have vesting criteria aligned with retention and annual share price growth over 3 years. Of these, 1,853,372 options (equivalent to 2% of issued share capital) have been issued to the CEO, Bram Goorden, and 926,686 options (equivalent to 1% of issued share capital) have been issued to the CFO, Grant Nash. These options have an exercise price of £0.01 and will be subject to a hold period to the third anniversary of their award.

The achievement of share price growth each year shall be measured by calculating the 3-month average share price immediately prior to each anniversary of the option award. The growth performance can be met in full by an absolute compound share price growth of 40% over the three-year period or in part by a 40% share price growth as compared to the prior year. In the first year this shall be compared to a baseline price equivalent to the three-month average share price immediately prior to the CEO joining the Company on 19 August 2024.

Retention options:

Share Options over a further 740,000 shares are awarded to the broader leadership team of the Company, including 200,000 Share Options awarded to the Robin Wolz, CSO who is treated as a PDMR. These Share Options have an exercise price of £0.0925 and have vesting criteria aligned with retention of these individuals in the business across 3 years.

For further information please contact:

IXICO plc

Bram Goorden, Chief Executive Officer
Grant Nash, Chief Financial Officer

+44 (0) 20 3763 7499

Cavendish Capital Markets Limited

(Nominated adviser and sole broker)

Giles Balleny / Dan Hodgkinson (Corporate Finance)
Nigel Birks (Life Sciences Specialist Sales)
Harriet Ward (Corporate Broking)
Michael F Johnson / Tamar Cranford Smith (Sales)

+44 (0) 20 7220 0500

About IXICO

IXICO is dedicated to delivering insights in neuroscience to help transform the advancement of investigational therapies for neurological diseases, such as Huntington's disease, Parkinson's disease and Alzheimer's disease. The Company's purpose is to advance medicine and human health by turning data into clinically meaningful information, providing valuable new insights in neuroscience by supporting pharmaceutical companies across all phases of CNS clinical research. IXICO's goal is to be a leading advocate of artificial intelligence in medical image analysis.

IXICO has developed and deployed breakthrough data analytics, at scale, through its remote access technology platform, to improve the return on investment in drug development and reduce risk and uncertainty in clinical trials for the Company's pharmaceutical clients.

More information is available on www.IXICO.com and follow us on X (formerly Twitter) @IXICOnews

	associated					
a)	Name	Bram Goorden				
2	Reason for the notification					
a)	Position/status	Chief Executive Officer				
b)	Initial notification /Amendment	Initial				
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor					
a)	Name	IXCO plc				
b)	LEI	2138005M1F59O6HWSA97				
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted					
a)	Description of the financial instrument, type of instrument Identification code	Options over ordinary shares in IXCO plc ISIN: GB00BFXR4C20				
b)	Nature of the transaction	Grant of Share Options				
c)	Price(s) and volume(s)	<table border="1"> <thead> <tr> <th>Price(s)</th><th>Volume(s)</th></tr> </thead> <tbody> <tr> <td>1 pence</td><td>1,853,372</td></tr> </tbody> </table>	Price(s)	Volume(s)	1 pence	1,853,372
Price(s)	Volume(s)					
1 pence	1,853,372					
d)	Aggregated information - Aggregated volume - Price	N/A - single transaction				
e)	Date of the transaction	30 October 2024				
f)	Place of the transaction	Off Market Transaction				

1	Details of the person discharging managerial responsibilities / person closely associated	
a)	Name	Grant Nash
2	Reason for the notification	
a)	Position/status	Chief Financial Officer
b)	Initial notification /Amendment	Initial
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor	
a)	Name	IXCO plc

b)	LEI	2138005M1F59O6HWSA97					
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted						
a)	Description of the financial instrument, type of instrument Identification code	Options over ordinary shares in IXICO plc ISIN: GB00BFXR4C20					
b)	Nature of the transaction	Grant of Share Options					
c)	Price(s) and volume(s)	<table><tr><td>Price(s)</td><td>Volume(s)</td></tr><tr><td>1 pence</td><td>926,686</td></tr></table>		Price(s)	Volume(s)	1 pence	926,686
Price(s)	Volume(s)						
1 pence	926,686						
d)	Aggregated information - Aggregated volume - Price	N/A - single transaction					
e)	Date of the transaction	30 October 2024					
f)	Place of the transaction	Off Market Transaction					

1	Details of the person discharging managerial responsibilities / person closely associated	
a)	Name	Robin Wolz
2	Reason for the notification	
a)	Position/status	Chief Scientific Officer and PDMR
b)	Initial notification /Amendment	Initial
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor	
a)	Name	IXICO plc
b)	LEI	2138005M1F59O6HWSA97
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted	
a)	Description of the financial instrument, type of instrument Identification code	Options over ordinary shares in IXICO plc ISIN: GB00BFXR4C20
b)	Nature of the transaction	Grant of Share Options

c)	Price(s) and volume(s)	<table><tr><td>Price(s)</td><td>Volume(s)</td></tr><tr><td>9.25p</td><td>200,000</td></tr></table>	Price(s)	Volume(s)	9.25p	200,000
Price(s)	Volume(s)					
9.25p	200,000					
d)	Aggregated information - Aggregated volume - Price	N/A - single transaction				
e)	Date of the transaction	30 October 2024				
f)	Place of the transaction	Off market				

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@seg.com or visit www.ms.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

DSHFDEEEELSEES